How long can resistance to Platinib last?

The maintenance time of drug resistance after taking platinib is a complex issue and is affected by many factors, including the patient's condition, physical condition, tumor type, specific forms of RET gene mutations, and individual differences in the treatment process.

The most common resistance mechanism is secondary mutations in target genes in cancer cells. These mutations may change the way the drug binds to its target, thereby reducing the drug's effectiveness. Cancer cells may activate alternative signaling pathways to bypass the inhibitory effects of platinib, for example by activating other kinases or growth factor pathways. Certain cancer cells may increase the expression of proteins that pump drugs out of the cell, thereby reducing the concentration of the drug within the cell.

There is currently no clear conclusion on the rate at which resistance to platinib develops. Some studies have shown that platinib can effectively inhibit tumor growth for a period of time, but as treatment continues, resistance may gradually emerge. For example, in some clinical trials, the median progression-free survival (PFS) for patients with non-small cell lung cancer treated with platinib ranged from 13 to 16 months, which may mean that resistance emerges in these patients around this time. However, this is only a rough estimate and may not apply to all patients.

The genetic background of the patient, especially the specific form of the RET gene mutation and the accompanying other genetic mutations. The patient's physical condition and immune function. The type and stage of the tumor. Selection of treatment options and dosage.

In order to delay the development of platinib resistance, other targeted drugs or immunotherapy can be combined to inhibit tumor growth through multiple mechanisms. Implement an individualized treatment plan and adjust the dosage and plan according to the patient's specific conditions. Regularly monitor patients' genetic mutation status to detect and respond to the emergence of drug resistance in a timely manner.